Dr. Y.K. Hamied submits SEBI Takeover Code disclosure under Regulations 31(4) and 31(5)
Under SEBI's Substantial Acquisition of Shares and Takeovers Regulations 2011, Regulation 31(4) and 31(5) mandate disclosure when a person acquires or ceases to hold shares or voting rights that cross key thresholds (typically 5%, 10%, 15%, 20%, 25%, 30%, etc.) or when control changes hands. The filing with NSE indicates a material event affecting Cipla's shareholding structure. No acquisition value or shareholding percentage is disclosed in the regulatory filing itself; the substance of the disclosure would be in the appended form.
Why it mattersSubstantial change in promoter shareholding or voting control has crystallised; review whether this signals a succession event, family restructuring, or pledge/encumbrance triggering disclosure thresholds under the Takeover Code.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- National Stock Exchange of India Limited - Corporate Announcements Archive · official
- SEBI - Takeover Regulations 2011 (Published Text) · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026